Latest & greatest articles for measles

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on measles or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on measles and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for measles

1. Measles-mumps-rubella vaccine (MMR): no link with autism

Measles-mumps-rubella vaccine (MMR): no link with autism Prescrire IN ENGLISH - Spotlight ''Measles-mumps-rubella vaccine (MMR): no link with autism'', 1 May 2020 {1} {1} {1} | | > > > Measles-mumps-rubella vaccine (MMR): no link with autism Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Measles-mumps-rubella vaccine (MMR): no link with autism (...) FEATURED REVIEW Studies based on a very significant number of children, taken together, do not show any link between MMR vaccination and the occurrence of autistic disorders. The authors of the two studies claiming the opposite used incorrect data or applied inappropriate analytical methods. Full review (3 pages) available for download by subscribers. Abstract Studies proposing a link between the measles-mumps-rubella vaccine (MMR) and autism were published in 1998 and 2014, and then retracted because

2020 Prescrire

2. What Is the Evidence to Support a Correlate of Protection for Measles? A Systematic Review. (Full text)

What Is the Evidence to Support a Correlate of Protection for Measles? A Systematic Review. Many studies assume that the serologic correlate of protection from measles disease is 120 mIU/mL. We systematically reviewed the literature to examine the evidence supporting this correlate of protection.We searched peer-reviewed and gray literature for articles reporting a measles correlate of protection. We excluded studies focusing on special populations, infants aged <9 months, and those using (...) animal models or nonstandard vaccines or administration routes. We extracted and synthesized data from full-text articles that met inclusion criteria.We screened 14 778 articles and included 5 studies in our review. The studies reported either preexposure antibody concentrations of individuals along with a description of symptoms postexposure, or the proportion of measles cases that had preexposure antibody concentrations above a threshold of immunity specified by the authors. Some studies also

2020 The Journal of infectious diseases PubMed abstract

3. Vaccines for measles, mumps, rubella, and varicella in children. (Abstract)

Vaccines for measles, mumps, rubella, and varicella in children. Measles, mumps, rubella, and varicella (chickenpox) are serious diseases that can lead to serious complications, disability, and death. However, public debate over the safety of the trivalent MMR vaccine and the resultant drop in vaccination coverage in several countries persists, despite its almost universal use and accepted effectiveness. This is an update of a review published in 2005 and updated in 2012.To assess (...) the effectiveness, safety, and long- and short-term adverse effects associated with the trivalent vaccine, containing measles, rubella, mumps strains (MMR), or concurrent administration of MMR vaccine and varicella vaccine (MMR+V), or tetravalent vaccine containing measles, rubella, mumps, and varicella strains (MMRV), given to children aged up to 15 years.We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (the Cochrane Library 2019, Issue 5), which includes the Cochrane Acute Respiratory

2020 Cochrane

4. Effect of age at vaccination on the measles vaccine effectiveness and immunogenicity: systematic review and meta-analysis. (Full text)

Effect of age at vaccination on the measles vaccine effectiveness and immunogenicity: systematic review and meta-analysis. The objectives of this review were to evaluate the effect of age at administration of the first dose of a measles-containing vaccine (MCV1) on protection against measles and on antibody response after one- and two-dose measles vaccinations.We conducted a systematic review of the PubMed/MEDLINE, Embase, Web of Science and Cochrane databases (1964-2017) to identify (...) observational studies estimating vaccine effectiveness and/or measles attack rates by age at first vaccination as well as experimental studies comparing seroconversion by age at first vaccination. Random effect models were used to pool measles risk ratios (RR), measles odds ratios (OR) and seroconversion RR of MCV1 administered at < 9, 9-11 or ≥ 15 months compared with 12 or 12-14 months of age.We included 41 and 67 studies in the measles protection and immunogenicity analyses. Older age at MCV1, from 6

2020 BMC infectious diseases PubMed abstract

5. Resurgence of Measles in Europe: A Systematic Review on Parental Attitudes and Beliefs of Measles Vaccine. (Full text)

Resurgence of Measles in Europe: A Systematic Review on Parental Attitudes and Beliefs of Measles Vaccine. Europe has experienced a major resurgence of measles in recent years, despite the availability and free access to a safe, effective, and affordable vaccination measles, mumps and rubella vaccine (MMR). The main driver for this is suboptimal vaccine coverage. The three objectives of this study are to synthesize and critically assess parental attitudes and beliefs toward MMR uptake (...) , 20 high-quality studies were identified. Vaccine hesitancy or refusal were mainly due to concerns about vaccine safety, effectiveness, perception of measles risk and burden, mistrust in experts, and accessibility. Factors for MMR uptake included a sense of responsibility toward child and community health, peer judgement, trust in experts and vaccine, and measles severity. Anthroposophical and Gypsy, Roma, and Traveler populations presented unique barriers such as accessibility.A multi

2020 Journal of epidemiology and global health PubMed abstract

6. Consequences of Undervaccination - Measles Outbreak, New York City, 2018-2019. (Abstract)

Consequences of Undervaccination - Measles Outbreak, New York City, 2018-2019. Measles was declared eliminated in the United States in 2000, but the risk of outbreaks owing to international importations remains. An outbreak of measles in New York City began when one unvaccinated child returned home from Israel with measles; onset of rash occurred on September 30, 2018, 9 days after the child returned home.We investigated suspected cases of measles by conducting interviews, reviewing medical (...) and immunization records, identifying exposed persons, and performing diagnostic testing. Measles-mumps-rubella (MMR) vaccine (given as either MMR or measles-mumps-rubella-varicella vaccine and collectively referred to as MMR vaccine) uptake was monitored with the use of the Citywide Immunization Registry. The total direct cost to the New York City Department of Health and Mental Hygiene was calculated.A total of 649 cases of measles were confirmed, with onsets of rash occurring between September 30, 2018

2020 NEJM

7. The effect of time since measles vaccination and age at first dose on measles vaccine effectiveness - A systematic review. (Full text)

The effect of time since measles vaccination and age at first dose on measles vaccine effectiveness - A systematic review. In settings where measles has been eliminated, vaccine-derived immunity may in theory wane more rapidly due to a lack of immune boosting by circulating measles virus. We aimed to assess whether measles vaccine effectiveness (VE) waned over time, and if so, whether differentially in measles-eliminated and measles-endemic settings.We performed a systematic literature review (...) of studies that reported VE and time since vaccination with measles-containing vaccine (MCV). We extracted information on case definition (clinical symptoms and/or laboratory diagnosis), method of vaccination status ascertainment (medical record or vaccine registry), as well as any biases which may have arisen from cold chain issues and a lack of an age at first dose of MCV. We then used linear regression to evaluate VE as a function of age at first dose of MCV and time since MCV.After screening 14,782

2020 Vaccine PubMed abstract

8. Safety and Immunogenicity of Measles Vaccination in HIV-Infected and HIV-Exposed Uninfected Children: A Systematic Review and Meta-Analysis. (Full text)

Safety and Immunogenicity of Measles Vaccination in HIV-Infected and HIV-Exposed Uninfected Children: A Systematic Review and Meta-Analysis. HIV-infected and HIV-exposed uninfected (HEU) children have an increased risk of measles that may be due to altered immune responses or suboptimal timing of measles vaccination. We aimed to evaluate the safety and immunogenicity of measles vaccination in HIV-infected and HEU children.For this systematic review and meta-analysis, we searched PubMed, Embase (...) , Cochrane Library, CINAHL, Global Health Library and IndMED on May 9, 2018. Studies were included if they reported on safety or seroresponse (either seroprotection/seropositivity/seroconversion) after measles vaccination in HIV-infected or HEU children. We calculated pooled estimates to compare immunogenicity outcomes between HIV-infected, HEU and HIV-unexposed children, using risk ratios [RRs] (with 95%CIs). PROSPERO registration number: CRD42017057411.Seventy-one studies met the inclusion criteria

2020 Eclinicalmedicine PubMed abstract

9. Estimates of case-fatality ratios of measles in low-income and middle-income countries: a systematic review and modelling analysis. (Full text)

Estimates of case-fatality ratios of measles in low-income and middle-income countries: a systematic review and modelling analysis. In the 21st century, increases in immunisation coverage and decreases in under-5 mortality have substantially reduced the global burden of measles mortality. However, the assessment of measles mortality burden is highly dependent on estimates of case-fatality ratios for measles, which can vary according to geography, health systems infrastructure, prevalence (...) of underlying risk factors, and measles endemicity. With imprecise case-fatality ratios, there is continued uncertainty about the burden of measles mortality and the effect of measles vaccination. In this study, we aimed to update the estimations of case-fatality ratios for measles, to develop a prediction model to estimate case-fatality ratios across heterogeneous groupings, and to project future case-fatality ratios for measles up to 2030.We did a review of the literature to identify studies examining

2020 The Lancet. Global health PubMed abstract

10. Measles in pregnant women: A systematic review of clinical outcomes and a meta-analysis of antibodies seroprevalence. (Abstract)

Measles in pregnant women: A systematic review of clinical outcomes and a meta-analysis of antibodies seroprevalence. Pregnant women represent a category at high risk of severe measles infection, that negatively affects the fetus as well. A systematic review of clinical outcomes of measles infection in gravid subjects and a meta-analysis of antibodies prevalence among pregnant women was conducted.MEDLINE and EMBASE databases were searched up to 18 June 2018. The screening focused on: (i (...) ) articles describing the outcome of measles in pregnancy, synthesized in a descriptive fashion; (ii) articles addressing the measles seroprevalence in cohorts of gravid women, analysed quantitatively.Twenty-nine articles met inclusion criteria. A total of 420 cases of measles in gravid subjects were described, from 1941 to 2012. Among women, 18 deaths (4.3%) occurred, and the most frequent complication was pneumonia (75/420, 17.9%). Prematurity was the most important complication concerning fetal

2020 The Journal of infection

11. Cost-effectiveness of measles treatment: a systematic review. (Abstract)

Cost-effectiveness of measles treatment: a systematic review. Measles is still common in many developing countries, and its outbreaks have been on the rise since 2009 even though the disease is almost entirely preventable through safe and effective vaccination. This paper aims to provide evidence about the systematic review of the cost-effectiveness of measles treatment in different regions worldwide.The methodical search began on 10th January 2019 to look for all articles on the cost (...) -effectiveness of measles treatment published from January 2019 to April 2019 in SCOPUS, Pubmed (www.ncbi.nlm.nih.gov) and Cochrane (www.cochrane.org).We summarised the articles by using a data table to extract all information using health economic evaluation methods.We identified 14 articles from the 69 total articles searched. These articles showed favourable costeffectiveness or cost-benefit ratios in high- and middle-income countries based on data organised by World Bank Income Level in 2018: the United

2020 JPMA. The Journal of the Pakistan Medical Association

12. Intralesional measles-mumps-rubella is associated with a higher complete response in cutaneous warts: a systematic review and meta-analysis of randomized controlled trial including GRADE qualification. (Abstract)

Intralesional measles-mumps-rubella is associated with a higher complete response in cutaneous warts: a systematic review and meta-analysis of randomized controlled trial including GRADE qualification. Introduction: Warts can be difficult to treat and progressing to chronic and resistant disease. Several studies have reported the successful application of mumps-measles-rubella (MMR) vaccine resulting in clearance of warts via immunomodulation and induction of immune system.Methods: We performed

2020 The Journal of dermatological treatment

13. National measles guidelines

National measles guidelines National measles guidelines - GOV.UK GOV.UK uses cookies which are essential for the site to work. We also use non-essential cookies to help us improve government digital services. Any data collected is anonymised. By continuing to use this site, you agree to our use of cookies. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Guidance National measles guidelines How to manage cases of suspected measles: what patient details to take, who (...) case of measles is ‘likely’ or ‘unlikely’ case management – what lab tests should be done and the importance of oral fluid testing on all suspected cases measles control – identifying vulnerable contacts and assessing their need for post-exposure prophylaxis Published 28 October 2010 Last updated 2 December 2019 2 December 2019 Added latest version of guidelines. 11 August 2017 Updated to reflect revised clinical advice. 28 October 2010 First published. Related content Collection Explore the topic

2019 Public Health England

14. Practice Advisory: Management of Pregnant and Reproductive-Aged Women during a Measles Outbreak

of reported cases of measles, also known as rubeola, since the disease was eliminated in 2000 1 . Outbreaks have been confirmed in 22 states and the number of cases and their distribution is increasing rapidly. These measles outbreaks have been linked to travelers bringing back cases of measles from other countries. This situation combined with low vaccination coverage among certain communities in the United States leads to pockets of vulnerable communities and contributes to outbreaks such as the one we (...) (GA): CDC; 2019. Available at: . Retrieved April 24, 2019. Centers for Disease Control and Prevention. Measles (rubeola): for healthcare professionals. Atlanta (GA): CDC; 2018. Available at: . Retrieved April 24, 2019. Atmar RL, Englund JA, Hammill H. Complications of measles during pregnancy. Clin Infect Dis 1992;14:217-26. Available at: . Retrieved April 24, 2019. McLean HQ, Fiebelkorn AP, Temte JL, Wallace GS. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary

2019 American College of Obstetricians and Gynecologists

15. Completeness and timeliness of diphtheria-tetanus-pertussis, measles-mumps-rubella, and polio vaccines in young children with chronic health conditions: A systematic review. (Full text)

Completeness and timeliness of diphtheria-tetanus-pertussis, measles-mumps-rubella, and polio vaccines in young children with chronic health conditions: A systematic review. To systematically review literature on uptake and timeliness of diphtheria-tetanus-pertussis, measles-mumps-rubella, and/or polio-containing vaccines ininfants who were born preterm, with a low birth weight, and/or with chronic health conditions that were diagnosed within the first 6 months of life.Using a standardized

2019 Vaccine PubMed abstract

16. Measles: public health response to cases who have travelled by air whilst infectious

Measles: public health response to cases who have travelled by air whilst infectious Measles: public health response to cases who have travelled by air whilst infectious - GOV.UK GOV.UK uses cookies which are essential for the site to work. We also use non-essential cookies to help us improve government digital services. Any data collected is anonymised. By continuing to use this site, you agree to our use of cookies. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search (...) Register by 26 November to vote in the General Election on 12 December. Guidance Measles: public health response to cases who have travelled by air whilst infectious Guidance about infectious measles on a flight (or international travel) for public health staff, passengers and crew. Published 26 June 2012 Last updated 28 October 2019 — From: Documents Ref: PHE gateway number 2018702 If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format

2019 Public Health England

17. What is the role of serologic testing for immunity to measles during an outbreak?

What is the role of serologic testing for immunity to measles during an outbreak? What Is The Role Of Serologic Testing For Immunity To Measles During An Outbreak? – Clinical Correlations Search What Is The Role Of Serologic Testing For Immunity To Measles During An Outbreak? September 18, 2019 6 min read By Sandra Goldlust Peer Reviewed Measles was declared eliminated from the US in 2000. Our country, however, is currently in the midst of the largest measles outbreak since 1992. As of July (...) preschool closures for failure to comply with , 5 and controversial bans on unvaccinated children from entering schools, . 6 Measles is a highly transmissible virus with a basic reproductive number (R 0 ) of 12-18. The R 0 represents the average number of secondary cases resulting from a single primary case in a totally susceptible population. This translates to a need to vaccinate about 93% of the population in order to disrupt measles transmission and achieve herd immunity. 7 Maintaining population

2019 Clinical Correlations

18. Proquad (Measles, Mumps, Rubella and Varicella Virus Vaccine Live)

Proquad (Measles, Mumps, Rubella and Varicella Virus Vaccine Live) Terms of use - Canada.ca Language selection Search Search Canada.ca Search Topics menu Main Menu You are here: Terms of use From These Terms of Use govern the access and use of Clinical Information released by Health Canada for non-commercial purposes. By clicking the button “I agree” and accepting these Terms of Use and upon being granted access to the Clinical Information, you, and, if applicable, the organization on behalf

2019 Health Canada - drugs and medical devices

19. Immunogenicity, effectiveness, and safety of measles vaccination in infants younger than 9 months: a systematic review and meta-analysis. (Full text)

Immunogenicity, effectiveness, and safety of measles vaccination in infants younger than 9 months: a systematic review and meta-analysis. Measles is an important cause of death in children, despite the availability of safe and cost-saving measles-containing vaccines (MCVs). The first MCV dose (MCV1) is recommended at 9 months of age in countries with ongoing measles transmission, and at 12 months in countries with low risk of measles. To assess whether bringing forward the age of MCV1 (...) -confirmed measles virus infection was 94% (95% CI 74-98) in infants vaccinated with MCV1 at 4·5 months of age. The pooled vaccine effectiveness of MCV1 in infants younger than 9 months against measles was 58% (95% CI 9-80; I2=84·9%, p<0·0001). The pooled vaccine effectiveness estimate from within-study comparisons of infants younger than 9 months vaccinated with MCV1 were 51% (95% CI -44 to 83; I2=92·3%, p<0·0001), and for those aged 9 months and older at vaccination it was 83% (76-88; I2=93·8%, p<0

2019 Lancet infectious diseases PubMed abstract

20. Effect of measles vaccination in infants younger than 9 months on the immune response to subsequent measles vaccine doses: a systematic review and meta-analysis. (Full text)

Effect of measles vaccination in infants younger than 9 months on the immune response to subsequent measles vaccine doses: a systematic review and meta-analysis. Vaccinating infants with a first dose of measles-containing vaccine (MCV1) before 9 months of age in high-risk settings has the potential to reduce measles-related morbidity and mortality. However, there is concern that early vaccination might blunt the immune response to subsequent measles vaccine doses. We systematically reviewed (...) schedule with MCV1 vaccination before 9 months of age was 95% (95% CI 89-100; I2=12·6%, p=0·29). Seven studies reporting on measles virus-specific cellular immune responses found that T-cell responses and T-cell memory were sustained, irrespective of the age of MCV1 administration. Overall, the quality of evidence was moderate to very low.Our findings suggest that administering MCV1 to infants younger than 9 months followed by additional MCV doses results in high seropositivity, vaccine effectiveness

2019 Lancet infectious diseases PubMed abstract